BioMerieux, Knome Team on Sequencing-Based MDx | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BioMérieux and Knome announced today that they will collaborate on developing next-generation sequencing-based molecular diagnostics.

The collaboration includes the French diagnostics firm taking a $5 million equity stake in Knome. Though the firms did not disclose the details of the investment or further financial terms, they said that BioMérieux has the right to designate one director for election to the board of directors of privately held Knome.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.